Combiflex Lipid Peripheral

Adult administration

For adults, the dosage and infusion rate should be determined according to the capacity to metabolize fats and glucose, with the dosage and bag size decided based on the patient's condition, weight, and nutritional needs. - For patients with normal nutritional status or mild metabolic stress: as amino acids, 0.7 to 1.0 g/kg (0.10 to 0.15 g nitrogen/kg) per day. - For patients under intermediate to high metabolic stress: as amino acids, 1.0 to 2.0 g/kg (0.15 to 0.30 g nitrogen/kg) per day via drip infusion.

This medication must be used according to a doctor's instructions. If symptoms of anaphylactic reactions such as fever, chills, rash, or respiratory distress occur during use, administration should be stopped immediately. When administering this drug together with intravenous calcium-containing preparations, do not mix with ceftriaxone, and if using the same infusion line, it must be thoroughly flushed. Caution should be used in premature or low-weight infants as the lipid components of this drug may not be well removed from the body and may pose risks. Patients with allergies to egg or soybean protein and those with severe liver dysfunction, hyperlipidemia, blood coagulation disorders should not use this medication. Patients with renal failure, pancreatitis, diabetic dyslipidemia, or other lipid metabolism issues should use this medication cautiously, with frequent monitoring of serum lipid levels, electrolyte levels, and liver and kidney functions during administration. This drug may cause side effects such as fever, chills, nausea, vomiting, temporary increase in liver enzymes, thrombophlebitis, skin rash, urticaria, hyperventilation, hypertension, hypotension, hemolysis, reticulocytosis, abdominal pain, headache, fatigue, priapism, hyperlipidemia, fat deposition, liver enlargement, spleen enlargement, anemia, leukopenia, thrombocytopenia, blood coagulation abnormalities. During the initial intravenous administration, the patient's condition should be carefully monitored, and if abnormal signs occur, administration should be stopped immediately. Before administration, ensure that serum electrolyte levels are normal, and during central venous administration, strict aseptic technique should be followed to prevent infections. This drug should not be infused simultaneously with blood, and blood glucose, electrolyte, and liver enzyme levels should be regularly monitored during administration. The safety of this medication in pregnant or breastfeeding women has not been established, and it should only be used when the therapeutic benefits outweigh the risks. Elderly patients may have decreased bodily function, so infusion rates should be slower, and dosages adjusted as needed. Overdosage may cause symptoms like nausea, vomiting, fluid overload, electrolyte imbalance, requiring cessation of administration or slowing down the rate, and blood dialysis may be necessary if needed. This medication should not be used if the packaging is damaged or if the solution is cloudy or separated, and should be stored between 0 to 25 degrees Celsius without freezing.

Serious side effects

Anaphylactic reaction (urticaria, severe swelling, chest tightness, difficulty breathing, cold sweat, pallor), severe skin reactions (severe rash with high fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes), respiratory issues (shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever), liver abnormalities (jaundice of skin or eyes, extreme fatigue), serious neurological symptoms (sudden and

Mild side effects

• Fever
• chills
• nausea
• vomiting
• temporary increase in liver enzymes
• thrombophlebitis
• skin rash
• urticaria
• hyperventilation
• hypertension

This medication should be stored in a sealed container to prevent exposure to air, and the storage temperature must be maintained between 0 and 25 degrees Celsius. Maintaining the appropriate temperature and sealed condition will safely preserve the drug's effectiveness.

Appearance

This drug consists of a plastic material for infusion divided into 3 compartments with an oxygen absorber in between them. Each internal compartment contains a dextrose solution, amino acids, and

Package unit

384ml (Component A: 236ml, Component B: 80ml, Component C: 68ml)/bag, 1040ml (Component A: 639ml, Component B: 217ml, Component C: 184ml)/bag, 1440ml (Component A: 885ml, Component B: 300ml, Component C: 255ml)/bag, 1920ml (Component A: 1180ml, Component B: 400ml, Component C: 340ml)/bag